Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rainmed Medical Limited ( (HK:2297) ) has shared an announcement.
Rainmed Medical reported a sharp deterioration in top-line performance for 2025, with revenue halving to RMB19.2 million and gross profit dropping 62.3%, pushing gross margin down to 46.9%. The company attributed the year’s loss mainly to continued research and development, selling, and administrative expenses, alongside impairment charges on goodwill and financial assets.
Despite the revenue slump, net loss attributable to shareholders narrowed by about a third to RMB77.1 million, helped by reduced R&D and selling expenses and lower impairment charges compared with the prior year. The board decided not to recommend a final dividend, signaling an ongoing focus on conserving cash as the company works to manage losses and stabilize operations for stakeholders.
The most recent analyst rating on (HK:2297) stock is a Hold with a HK$0.25 price target. To see the full list of analyst forecasts on Rainmed Medical Limited stock, see the HK:2297 Stock Forecast page.
More about Rainmed Medical Limited
Rainmed Medical Limited is a Cayman Islands-incorporated medical technology company listed in Hong Kong that develops and sells medical devices. The group focuses on products for the healthcare sector, generating revenue from device sales and related solutions in the mainland China market and beyond.
Average Trading Volume: 592,258
Technical Sentiment Signal: Buy
Current Market Cap: HK$392.4M
For an in-depth examination of 2297 stock, go to TipRanks’ Overview page.